Description: Founded in 2018 as Quoin Pharmaceuticals Inc. by Michael Myers Ph.D. and Denise Carter, Quoin is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others.
Home Page: quoinpharma.com
QNRX Technical Analysis
42127 Pleasant Forest Court
Ashburn,
VA
20148-7349
United States
Phone:
703 980 4182
Officers
| Name | Title |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, CEO & Chairman |
| Ms. Denise Carter | Co-Founder, COO & Director |
| Mr. Gordon Bruce Dunn J.D. | Chief Financial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8247 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |